Aug 2026· Nano letters (Print)· Vol 26 34, pp.
11420-11431
· 0 citations· 68 references
Medicine
Abstract
Chemoresistance remains a major clinical challenge in osteosarcoma, primarily driven by inefficient drug delivery and the evasion of cell death. Here, a multifunctional poly(β-amino ester) (pBAE)-based therapeutic delivery system was developed for simultaneous codelivery of small interfering RNA (siRNA) and doxorubicin (DOX) to drug-resistant osteosarcoma cells. The system significantly enhanced siRNA transfection within 4 h and showed substantially enhanced cytotoxicity compared with free DOX at equivalent concentrations. Mechanistically, pBAE degraded in the acidic tumor microenvironment, facilitating siRNA and DOX release, which synergistically modulated apoptotic and pyroptotic signaling to induce cell death. In vivo studies in osteosarcoma-bearing mice demonstrated that pBAE-based treatment markedly suppressed tumor growth, reducing tumor volume by approximately 70% without significant adverse effects. This study presents a therapeutic strategy centered on the "enhanced delivery-induced cell death" paradigm, effectively overcoming osteosarcoma chemoresistance and designing multifunctional nanodelivery systems for cancer therapy.
Lung cancer remains the most commonly diagnosed malignancy and a leading cause of cancer-related mortality worldwide. Paclitaxel (PTX), a first-line chemotherapeutic agent for advanced non-small cell lung cancer (NSCLC), is frequently compromised by acquired drug resistance. Here, through network pharmacology analysis...
Ze-Jin Shen, Xu-Ran Kou, Ming-Yuan Wang et al.· Journal of Biomaterials Appl...· 0 citations
Traditional cancer therapies are constrained by tumor diversity, therapeutic resistance, and side effects, thereby necessitating the development of precise multimodal antitumor strategies. This work reports a relatively high-drug-loading polymeric nanoplatform, PSCT, for combined sonodynamic therapy and chemotherapy. C...
Lu Wang, Zhi-Bo Zhang, Qiao-Ni Liu et al.· Materials Today Bio· 0 citations
Background The clinical application of traditional chemotherapy for treating patients with lung cancer is restricted by its poor targeting efficacy and severe systemic toxicity. In this study, we developed an acid-sensitive lipid-polymer nanocapsule (PTX/Pt@RGD) for the co-delivery of a redox-sensitive paclitaxel (PTX)...
Xin-Yue Wang, Dan Qin, Chun-Yu Yao et al.· Translational Lung Cancer Re...· 0 citations
As a highly malignant tumor, melanoma is associated with poor prognosis and high recurrence rates. Despite advances in surgery, radiotherapy, chemotherapy, and immunotherapy, drug resistance and immune evasion remain major obstacles. Epigenetic dysregulationsuch as aberrant DNA methylation and histone deacetylation...
Yue-Zhu Zhao, Jie Ma, Yue Xu et al.· ACS Applied Nano Materials· 0 citations
Background/Objectives: Cancer causes high premature death worldwide, with 35 million new cases expected by 2050. Multidrug resistance (MDR), driven by genetic and epigenetic changes, hampers chemotherapy. In this study, polymeric nanoparticles (NPs) were formulated with an organoselenium nucleoside analogue (AFAT-Se) t...
Bruna Fracari Do Nascimento, Bianca Costa Maia-do-Amaral, Taís Baldissera Pieta et al.· Future Pharmacology· 0 citations
The therapeutic efficacy of cancer immunotherapy is impaired by poor tumor immunogenicity and the immunosuppressive tumor microenvironment (TME), partially driven by reprogrammed adenosine metabolism in the tumor. Here, we develop degradable CRISPR/Cas9 nanoparticles to durably and precisely downregulate CD73 expressio...
Xin-Hong Sun, Yu-Jing Sang, Teng-Fei He et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.